Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.

OBJECTIVE:The objective of this study was to evaluate the antitumor effects of lurbinectedin as a single agent or in combination with existing anticancer agents for clear cell carcinoma (CCC) of the ovary, which is regarded as an aggressive, chemoresistant, histological subtype. METHODS:Using human...

Full description

Bibliographic Details
Main Authors: Ryoko Takahashi, Seiji Mabuchi, Mahiru Kawano, Tomoyuki Sasano, Yuri Matsumoto, Hiromasa Kuroda, Katsumi Kozasa, Kae Hashimoto, Kenjiro Sawada, Tadashi Kimura
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4795692?pdf=render

Internet

http://europepmc.org/articles/PMC4795692?pdf=render

Similar Items